RadNet (NASDAQ:RDNT) 株価情報

RADNET INC

RadNet

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.

RadNet Inc

<ul>
<li>See-Mode's commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet's DeepHealth population health solutions</li>
<li>Real-world deployment of See-Mode's FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy</li>
<li>The acquisition positions RadNet at the forefront of AI innovation in ultrasound &nbsp;</li>
</ul>
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions through its wholly-owned subsidiary DeepHealth, announced today that it has completed the acquisition of See-Mode Technologies PTE LTD ("See-Mode"), a global innovator in AI for ultrasound imaging. See-Mode's initial applications to detect and characterize thyroid nodules and breast lesions in ultrasound imaging improve diagnostic accuracy and enhance clinical workflows by generating standardized reports.1 These applications and others to be developed in the future using See-Mode's technology and expertise will strengthen DeepHealth's leadership in population health solutions.

RDNT

RadNet Acquires See-Mode Technologies To Boost DeepHealth's Population Health Solutions; No Financial Terms Disclosed

News

Guidance

RadNet Raises FY2025 Sales Guidance from $1.825B-$1.875B to $1.835B-$1.885B vs $1.936B Est

RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.13) by 169.23 percent. This is a 600 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $471.40 million which beat the analyst consensus estimate of $443.23 million by 6.36 percent. This is a 9.19 percent increase over sales of $431.71 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

RadNet Q1 Adj. EPS $(0.35) Misses $(0.13) Estimate, Sales $471.40M Beat $443.23M Estimate

U.S. stock futures declined on Wednesday following a muted day of trading on Tuesday. Futures of major benchmark indices were lower in premarket.
The Donald Trump administration levied a<a href="https://www.benzinga.com/markets/25/04/44831287/trump-administration-imposes-up-to-245-tariff-on-chinese-imports-amid-intensifying-trade-battle"> 245% tariff on China</a> late Tuesday. &#8220;China now faces up to a 245% tariff on imports to the United States as a result of its retaliatory actions,&#8221; stated a White House fact sheet.
Meanwhile, the new U.S. export restrictions halting the shipments of Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)<a href="https://benzinga.com/25/04/44830406/nvidia-to-take-55-billion-hit-over-china-chip-export-restrictions-but-top-analyst-dan-ives-says-hes-not-overly-concerned-all-part-of-the-high-game-of-poker"> H20 graphics processing units to China</a> were announced. The announcement comes after the U.S. government informed the company on April 9 that it would now require a license to export those chips.
The 10-year Treasury bond yielded 4.31% and the two-year bond was at 3.81%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool&#8217;s </a>projections show markets pricing a 79.9% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.07%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.44%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.08%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.35%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Wednesday. The SPY was down 0.67% to $534.02, while the QQQ declined 1.27% to $452.17, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Weighing on U.S. stocks Tuesday, the consumer discretionary, health care, and consumer staples sectors saw the biggest declines.
Bucking the trend, however, information technology and real estate stocks closed higher.
The market moves came as Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) and Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) reported better-than-expected first-quarter earnings, while economic data showed a rise in the NY Empire State Manufacturing Index and flat export prices alongside a slight drop in import prices for March.
The Dow closed Tuesday 10.44% below its 52-week peak of 45,073.63. The S&amp;P 500 ended 12.21% off its 6,147.43 high, and the Nasdaq 100 was 15.27% below its 22,222.61 record.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.049%</td>
<td>16,823.17</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.17%</td>
<td>5,396.63</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.38%</td>
<td>40,368.96</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.11%</td>
<td>1,882.92</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to Mona Mahajan of Edward Jones, the stock valuations were not stretched anymore. &#8220;While market returns have been negative this year, the upside is that valuations are now looking more compelling and are no longer stretched, which was a concern coming into this year.&#8221;
She highlighted that all major indexes were trading at or below their 10-year historical forward price-to-earnings multiples, potentially setting the stage for improved long-term returns.
The S&amp;P 500 forward multiple was around 18 times next year&#8217;s earnings forecast, down from a recent high of 22.7 times, while the Nasdaq forward multiple was about 21 times, down from its recent high of 30 times.
&#8220;In our view, the spike in volatility, a reset in valuations, and signs that the worst-case scenario in the trade war appears to be averted suggest that stocks may find some support and try to carve out a bottom. Risks have risen, but a recession is not inevitable in our view, and stocks appear to have already priced in a significant degree of bad outcomes,&#8221; she added.
Jason Goepfert of White Oak Consultancy LLC noted a historical pattern: whenever the VIX fear index drops from above 50 to the 30 level, the S&amp;P 500 has historically achieved 100% positive gains by year-end.
However, he points out that in the most recent such cycle in May 2020, the S&amp;P 500&#8217;s return after a year was 42.96%. Goepfert&#8217;s analysis of similar cycles in 2009, 2002, and 1988 also reveals a short-term median loss of 0.7% for the S&amp;P 500 in the week following the VIX&#8217;s drop to 30.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The VIX cycle from &gt; 50 to &lt; 30 is on track to trigger today. A bear killer. <a href="https://t.co/rzvdiBw37G">pic.twitter.com/rzvdiBw37G</a>
&mdash; Jason Goepfert (@jasongoepfert) <a href="https://twitter.com/jasongoepfert/status/1912145727448363174?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to an X post by Charlie Bilello of Creative Planning, historical data since 1990 showed that the S&amp;P 500 has delivered an average return of 35% in the year following a VIX close above 50, and 129% over the subsequent five years.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The <a href="https://twitter.com/search?q=%24VIX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$VIX</a> closed above 50 last week for the first time since April 2020. In the past, what has that meant for stocks going forward? Video discussion: <a href="https://t.co/YYVlqL4IlH">https://t.co/YYVlqL4IlH</a> <a href="https://t.co/iEy9Wb5myJ">pic.twitter.com/iEy9Wb5myJ</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1912220992963035233?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Wednesday:
<ul>
<li>March&#8217;s U.S. retail sales will be out by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Industrial production and capacity utilization data for March will be announced at 9:15 a.m. ET.</li>
</ul>
<ul>
<li>Business inventories for February and the home builder confidence index for April will be out by 10:00 a.m. ET.</li>
</ul>
<ul>
<li>Cleveland Fed President Beth Hammack will speak at noon.</li>
</ul>
Stocks In Focus:
<ul>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) rose 0.74% in premarket on Wednesday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $1.07 per share on revenue of $10.40 billion.</li>
</ul>
<ul>
<li>Travelers Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) was up 0.076% as Wall Street expects it to report earnings of 80 cents per share on revenue of $10.82 billion before the opening bell.</li>
</ul>
<ul>
<li>Progressive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) fell 0.01% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $4.81 per share on revenue of $21.63 billion.</li>
</ul>
<ul>
<li>ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) dropped 4.2% despite beating earnings estimates as its revenue and EPS fell on a sequential basis.</li>
</ul>
<ul>
<li>J B Hunt Transport Services Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) dropped 6.28% after reporting a 7.6% decline in profit for the first quarter. The company posted quarterly revenue of $2.92 billion, compared to market estimates of $2.90 billion.</li>
</ul>
<ul>
<li>iCAD Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) surged 72.02% and Radnet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) fell 2.03% after they announced a definitive all-stock merger agreement where RadNet will acquire iCAD.</li>
</ul>
<ul>
<li>La Rosa Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) jumped 119.16% after Nasdaq granted a 180-day extension, until October 6, 2025, to regain the $1.00 minimum bid price for continued listing under &#8216;LRHC&#8217;.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.60% to hover around $61.70 per barrel.
Gold Spot US Dollar advanced 2.38% to hover around $3,304.35 per ounce. Its fresh record high stood at $3,318 per ounce. The U.S. Dollar Index spot was lower by 0.51% at the 99.7040 level.
Asian markets declined on Wednesday, except India's S&amp;P BSE Sensex, China&#8217;s CSI 300 index. Hong Kong's Hang Seng, Japan's Nikkei 225, Australia's ASX 200, and South Korea's Kospi index ended lower. European markets were also mostly lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44831287/trump-administration-imposes-up-to-245-tariff-on-chinese-imports-amid-intensifying-trade-battle">Trump Administration Imposes Up To 245% Tariff On Chinese Imports Amid Intensifying Trade Battle</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Futures

Commodities

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Markets

Analyst Ratings

ASML

ICAD

JBHT

LRHC

NVDA

US Stock Likely To Open Lower As US-China Tariff War Continues: 'Valuations Are Now Looking More Compelling,' Says Expert

<ul>
<li>The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer</li>
<li>The transaction is expected to add to RadNet's wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries</li>
<li>With iCAD's seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet's growth and leadership in cancer screening and artificial intelligence</li>
<li>Following the completion of the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio of solutions</li>
<li>RadNet will host a conference call and webcast at 10:30 a.m. ET tomorrow, April 16, 2025, to discuss the transaction &nbsp;</li>
</ul>
LOS ANGELES and NASHUA, N.H., April 15, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) ("iCAD"), a global leader in providing clinically proven AI-powered breast health solutions, announced today that they have entered into a definitive merger agreement under which RadNet will acquire iCAD in an all stock transaction.
Under the terms of the merger agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger.
Based upon RadNet's closing price on Monday, April 14, 2025, this represents a transaction value of approximately $103 million, or approximately $3.61 per share of iCAD common stock on a fully diluted basis and an approximately 98% premium to iCAD stockholders based on iCAD's closing stock price on Monday, April 14, 2025.

RadNet To Acquire iCAD; Under The Terms Of The Merger Agreement, iCAD Stockholders Will Receive 0.0677 Shares Of RadNet Common Stock For Each Share Of iCAD Common Stock; This Represents A Transaction Value Of ~$103M, Or $3.61/Share

In the preceding three months, 6 analysts have released ratings for RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for RadNet, presenting an average target of $73.5, a high estimate of $88.00, and a low estimate of $60.00. This current average represents a 16.16% decrease from the previous average price target of $87.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1744380068_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $74.00&#x7C;$88.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$74.00 &#x7C; 
&#x7C;John Ransom &#x7C;Raymond James &#x7C;Lowers &#x7C;Strong Buy &#x7C; $65.00&#x7C;$85.00 &#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $88.00&#x7C;$94.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $74.00&#x7C;$85.00 &#x7C; 
&#x7C;Brian Tanquilut &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $80.00&#x7C;$100.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to RadNet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for RadNet's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into RadNet's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on RadNet analyst ratings.</a>
<h2>Delving into RadNet's Background</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
<h3>Unraveling the Financial Story of RadNet</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: RadNet's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 13.49%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: RadNet's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 1.12%, the company may face hurdles in effective cost management.
Return on Equity (ROE): RadNet's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.59%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.16%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: RadNet's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.92.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where RadNet Stands With Analysts

Truist Securities analyst David Macdonald maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and lowers the price target from $88 to $74.

Price Target

Truist Securities Maintains Buy on RadNet, Lowers Price Target to $74

Ratings for RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for RadNet, presenting an average target of $73.4, a high estimate of $88.00, and a low estimate of $60.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.21%. 
<img src="https://www.benzinga.com/files/images/story/2025/1742824875_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of RadNet among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$65.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RadNet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of RadNet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of RadNet's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on RadNet analyst ratings.</a>
<h2>Discovering RadNet: A Closer Look</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
<h3>Key Indicators: RadNet's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: RadNet's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 13.49%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: RadNet's net margin is impressive, surpassing industry averages. With a net margin of 1.12%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): RadNet's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.59%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): RadNet's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.16%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: RadNet's debt-to-equity ratio is below the industry average. With a ratio of 1.92, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About RadNet

Barclays analyst Andrew Mok maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Overweight and lowers the price target from $74 to $60.

Barclays Maintains Overweight on RadNet, Lowers Price Target to $60

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Radnet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>)</h3>
<ul>
<li>On March 5, Raymond James analyst John Ransom upgraded RadNet from Outperform to Strong Buy and lowered the price target from $85 to $65.. The company's stock fell around 24% over the past month and has a <a href="https://www.benzinga.com/quote/RDNT">52-week low of $42.45</a>.</li>
<li>RSI Value: 24.8</li>
<li>RDNT Price Action: Shares of Radnet fell 4.1% to close at $47.24 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">RDNT news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/f7a3bd9f-ba79-4b8a-8bca-2d13a36aad09" alt="" style="width:586px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Tactile Systems Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 18, Tactile Systems Tech posted better-than-expected quarterly earnings. &#8220;Our fourth quarter results capped off a dynamic year for Tactile, during which we launched our next-generation lymphedema platform, generated clinical evidence supporting the value of our therapies, deployed new workflow-related tools to enhance speed and efficiency in order operations, and served over 79,000 patients with our lymphedema and airway clearance solutions,&#8221; said Sheri Dodd, President and Chief Executive Officer of Tactile Medical. The company's stock fell around 22% over the past month and <a href="https://www.benzinga.com/quote/KKR">has a 52-week low </a>of $11.12.</li>
<li>RSI Value: 22.5</li>
<li>TCMD Price Action: Shares of Tactile Systems Technology fell 4.7% to close at $13.26 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">TCMD stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13070346/image-94.png" alt="" class="wp-image-822659" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13070346/image-94.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13070346/image-94-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13070346/image-94-768x709.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">ProKidney Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>)</h3>
<ul>
<li>On Nov. 12, 2024, ProKidney posted a narrower-than-expected quarterly loss. The company's stock fell around 38% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/PIPR">low of $0.94</a>.</li>
<li>RSI Value: 25.9</li>
<li>PROK Price Action: Shares of ProKidney fell 5.3% to close at $0.99 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">PROK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="883" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13070510/image-95.png" alt="" class="wp-image-822670" style="width:573px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13070510/image-95.png 883w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13070510/image-95-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13070510/image-95-768x732.png 768w" sizes="(max-width: 883px) 100vw, 883px" /></a></figure>
Read This Next:<a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday">Adobe, Intel And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Long Ideas

Trading Ideas

PROK

TCMD

Top 3 Health Care Stocks You'll Regret Missing This Quarter

DAVID SWARTZ, Director at RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), reported an insider sell on March 12, according to a new SEC filing. 
What Happened: SWARTZ's decision to sell 25,000 shares of RadNet was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000790526/000168316825001530//Archives/edgar/data/790526/000168316825001530/0001683168-25-001530-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $1,271,000.
RadNet shares are trading up 0.71% at $49.59 at the time of this writing on Wednesday morning.
<h3>Get to Know RadNet Better</h3>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
<h3>Unraveling the Financial Story of RadNet</h3>
Positive Revenue Trend: Examining RadNet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.49% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: With a low gross margin of 13.76%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): RadNet's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.08.
</li>
</ul>
Debt Management: RadNet's debt-to-equity ratio is below the industry average. With a ratio of 1.92, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 1231.0, RadNet's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 2.01 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 14.34, RadNet presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000790526">Check Out The Full List Of RadNet's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Director Of RadNet Makes $1.27M Sale

In the latest quarter, 4 analysts provided ratings for RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for RadNet, presenting an average target of $76.75, a high estimate of $88.00, and a low estimate of $65.00. This current average represents a 15.66% decrease from the previous average price target of $91.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741204823_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of RadNet's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$65.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to RadNet. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of RadNet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into RadNet's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on RadNet analyst ratings.</a>
<h2>Get to Know RadNet Better</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Financial Insights: RadNet</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: RadNet displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.49%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: RadNet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): RadNet's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.59%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.16%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.92.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For RadNet

Raymond James analyst John Ransom upgrades RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) from Outperform to Strong Buy and lowers the price target from $85 to $65.

Upgrades

Raymond James Upgrades RadNet to Strong Buy, Lowers Price Target to $65

WIIM

RedNet shares are trading lower after the company issued FY25 revenue guidance below estimates.

RadNet Expects FY25 Total Net Revenue $1.825B - $1.875B, Est $1.979B

RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. The company reported quarterly sales of $477.10 million which beat the analyst consensus estimate of $461.79 million by 3.32 percent. This is a 13.49 percent increase over sales of $420.38 million the same period last year.

RadNet Q4 2024 Adj EPS $0.22 Beats $0.20 Estimate, Sales $477.10M Beat $461.79M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

RadNet Announced That OB/GYN  Specialists Of The Palm Beaches Is Launching Breast Imaging Services Across Multiple Locations In Palm Beach County, Utilizing Technologies From RadNet And Its Wholly-owned Subsidiary, Deephealth

RadNet Subsidiary DeepHealth Form Partnership With ConcertAI To Integrate AI And Advanced Visualization

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) is a &#8220;very <a href="https://www.benzinga.com/quote/FSLR/earnings">inexpensive&#8221; stock</a>.
First Solar, meanwhile, will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25, 2025.
<h3 class="wp-block-heading">Shares His Views On These Health Care Stocks</h3>
When asked about Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), Cramer said he prefers Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In the recent news, Viking Therapeutics, on Jan. 8, announced the initiation of Phase 2 VENTURE-oral dosing trial of VK2735 tablet formulation in patients with obesity.
&#8220;This group is just not strong enough, that includes this one. Let's give it a pause for a second,&#8221; Cramer said when asked about RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>). &#8220;It was a great stock for a long time, I need to see a real bottom.&#8221;
Barclays analyst Andrew Mok, on Jan. 22, maintained RadNet with an Overweight rating and lowered the price target from $85 to $74, while Truist Securities analyst David Macdonald reiterated the stock with a Buy and slashed the price target from $94 to $88.
<h3 class="wp-block-heading">Likes This Industrial Stock Very Much</h3>
The &#8220;Mad Money&#8221; host said he likes Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) very much, adding that it's an &#8220;absolutely terrific&#8221; stock. He added, &#8220;I would start a position right now.&#8221;
Supporting his view, Scotiabank analyst Konark Gupta, on Monday, upgraded Waste Management from Sector Perform to Sector Outperform and raised the price target from $225 to $250.
Price Action:
<ul>
<li>Viking Therapeutics shares gained 2.6% to settle at $34.32 on Tuesday.</li>
<li>First Solar shares fell 2.5% to close at $160.24 during the session.</li>
<li>RadNet shares gained 4.2% to settle at $65.94 on Tuesday.</li>
<li>Waste Management shares rose 0.01% to settle at $213.65 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43263799/wall-streets-most-accurate-analysts-spotlight-on-3-tech-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech &amp; Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Media

FSLR

VKTX

Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive'

Press Releases

RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD

RadNet, Inc. Announces Date of its First Quarter 2025 Financial Results Conference Call

GE HealthCare to feature latest advancements in diagnostic accuracy and patient-centered breast care at SBI 2025 Breast Cancer Imaging Symposium

Opinion

Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds

RadNet, Inc. to Present at the Bank of America Securities 2025 Healthcare Conference on May 13th, 2025

RadNet Reports First Quarter Financial Results and Revises Upwards 2025 Financial Guidance Ranges for Revenue and Adjusted EBITDA¹

Small Cap

Behind the FDA's AI Push: A Growing Class of Public Healthcare Innovators

Health Care

RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics

AVAI

GEHC

HWAIF

MCIOF

MSFT

TREN

TSX:AIDX

TSX:DRDR

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

RadNet

ニュース

パートナーシップ

ベンジンガ・グローバル